Live-attenuated Vaccine SCPD9 Elicits Superior Mucosal and Systemic Immunity to SARS-CoV-2 Variants in Hamsters

Vaccines play a critical role in combating the COVID-19 pandemic. Future control of the pandemic requires improved vaccines with high efficacy against newly emerging SARS-CoV-2 variants and the ability to reduce virus transmission. Here we compare immune responses and preclinical efficacy of the mRNA vaccine BNT162b2, the adenovirus-vectored spike vaccine Ad2-spike and the live-attenuated virus vaccine candidate sCPD9 in Syrian hamsters, using both homogeneous and heterologous vaccination regimens. Comparative vaccine efficacy was assessed by employing readouts from virus titrations to single-cell RNA sequencing. Our results show that sCPD9 vaccination elicited the most robust immunity, including rapid viral clearance, reduced tissue damage, fast differentiation of pre-plasmablasts, strong systemic and mucosal humoral responses, and rapid recall of memory T cells from lung tissue after challenge with heterologous SARS-CoV-2. Overall, our results demonstrate that live-attenuated vaccines offer advantages over currently available COVID-19 vaccines.

Citing Articles

Intranasal recombinant protein subunit vaccine targeting TLR3 induces respiratory tract IgA and CD8 T cell responses and protects against respiratory virus infection.

Worzner K, Schmidt S, Zimmermann J, Tami A, Polacek C, Fernandez-Antunez C EBioMedicine. 2025; 113:105615.

PMID: 39983329 PMC: 11893338. DOI: 10.1016/j.ebiom.2025.105615.

Immunogenicity and safety of a live-attenuated SARS-CoV-2 vaccine candidate based on multiple attenuation mechanisms.

Suzuki Okutani M, Okamura S, Gis T, Sasaki H, Lee S, Kashiwabara A Elife. 2025; 13.

PMID: 39932490 PMC: 11813227. DOI: 10.7554/eLife.97532.

Safety and Immunogenicity of the Live Attenuated Vaccine QazCOVID-Live Against Coronavirus Infection COVID-19: Pre-Clinical Study Results.

Kutumbetov L, Myrzakhmetova B, Tussipova A, Zhapparova G, Tlenchiyeva T, Bissenbayeva K Vaccines (Basel). 2025; 12(12.

PMID: 39772061 PMC: 11728456. DOI: 10.3390/vaccines12121401.

Antigenic Imprinting Dominates Humoral Responses to New Variants of SARS-CoV-2 in a Hamster Model of COVID-19.

Degryse J, Maas E, Lassauniere R, Geerts K, Kumpanenko Y, Weynand B Microorganisms. 2025; 12(12.

PMID: 39770793 PMC: 11678355. DOI: 10.3390/microorganisms12122591.

A statistical approach for systematic identification of transition cells from scRNA-seq data.

Wang Y, Dede M, Mohanty V, Dou J, Li Z, Chen K Cell Rep Methods. 2024; 4(12):100913.

PMID: 39644902 PMC: 11704623. DOI: 10.1016/j.crmeth.2024.100913.

References

Xia H, Zou J, Kurhade C, Cai H, Yang Q, Cutler M . Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2. Cell Host Microbe. 2022; 30(4):485-488.e3. PMC: 8853806. DOI: 10.1016/j.chom.2022.02.015. View

Di Pietrantonj C, Rivetti A, Marchione P, Debalini M, Demicheli V . Vaccines for measles, mumps, rubella, and varicella in children. Cochrane Database Syst Rev. 2020; 4:CD004407. PMC: 7169657. DOI: 10.1002/14651858.CD004407.pub4. View

Lin Y, Wen C, Lin Y, Hsieh W, Chang C, Chen Y . Oil-in-water emulsion adjuvants for pediatric influenza vaccines: a systematic review and meta-analysis. Nat Commun. 2020; 11(1):315. PMC: 6965081. DOI: 10.1038/s41467-019-14230-x. View

Hassan A, Shrihari S, Gorman M, Ying B, Yuan D, Raju S . An intranasal vaccine durably protects against SARS-CoV-2 variants in mice. Cell Rep. 2021; 36(4):109452. PMC: 8270739. DOI: 10.1016/j.celrep.2021.109452. View

Lauring A, Jones J, Andino R . Rationalizing the development of live attenuated virus vaccines. Nat Biotechnol. 2010; 28(6):573-9. PMC: 2883798. DOI: 10.1038/nbt.1635. View

Eschke K, Trimpert J, Osterrieder N, Kunec D . Attenuation of a very virulent Marek's disease herpesvirus (MDV) by codon pair bias deoptimization. PLoS Pathog. 2018; 14(1):e1006857. PMC: 5805365. DOI: 10.1371/journal.ppat.1006857. View

Coleman J, Papamichail D, Skiena S, Futcher B, Wimmer E, Mueller S . Virus attenuation by genome-scale changes in codon pair bias. Science. 2008; 320(5884):1784-7. PMC: 2754401. DOI: 10.1126/science.1155761. View

Oberhardt V, Luxenburger H, Kemming J, Schulien I, Ciminski K, Giese S . Rapid and stable mobilization of CD8 T cells by SARS-CoV-2 mRNA vaccine. Nature. 2021; 597(7875):268-273. PMC: 8426185. DOI: 10.1038/s41586-021-03841-4. View

Ssemaganda A, Nguyen H, Nuhu F, Jahan N, Card C, Kiazyk S . Expansion of cytotoxic tissue-resident CD8 T cells and CCR6CD161 CD4 T cells in the nasal mucosa following mRNA COVID-19 vaccination. Nat Commun. 2022; 13(1):3357. PMC: 9186487. DOI: 10.1038/s41467-022-30913-4. View

10.

Turner J, OHalloran J, Kalaidina E, Kim W, Schmitz A, Zhou J . SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature. 2021; 596(7870):109-113. PMC: 8935394. DOI: 10.1038/s41586-021-03738-2. View

11.

Laczko D, Hogan M, Toulmin S, Hicks P, Lederer K, Gaudette B . A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. Immunity. 2020; 53(4):724-732.e7. PMC: 7392193. DOI: 10.1016/j.immuni.2020.07.019. View

12.

Ren C, Gao Y, Zhang C, Zhou C, Hong Y, Qu M . Respiratory Mucosal Immunity: Kinetics of Secretory Immunoglobulin A in Sputum and Throat Swabs From COVID-19 Patients and Vaccine Recipients. Front Microbiol. 2022; 13:782421. PMC: 8914317. DOI: 10.3389/fmicb.2022.782421. View

13.

Sheikh-Mohamed S, Isho B, Chao G, Zuo M, Cohen C, Lustig Y . Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection. Mucosal Immunol. 2022; 15(5):799-808. PMC: 9037584. DOI: 10.1038/s41385-022-00511-0. View

14.

Beura L, Fares-Frederickson N, Steinert E, Scott M, Thompson E, Fraser K . CD4 resident memory T cells dominate immunosurveillance and orchestrate local recall responses. J Exp Med. 2019; 216(5):1214-1229. PMC: 6504216. DOI: 10.1084/jem.20181365. View

15.

Trimpert J, Adler J, Eschke K, Abdelgawad A, Firsching T, Ebert N . Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta). Sci Adv. 2021; 7(49):eabk0172. PMC: 8635430. DOI: 10.1126/sciadv.abk0172. View

16.

Trimpert J, Dietert K, Firsching T, Ebert N, Thao T, Vladimirova D . Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding. Cell Rep. 2021; 36(5):109493. PMC: 8289629. DOI: 10.1016/j.celrep.2021.109493. View

17.

Nouailles G, Wyler E, Pennitz P, Postmus D, Vladimirova D, Kazmierski J . Temporal omics analysis in Syrian hamsters unravel cellular effector responses to moderate COVID-19. Nat Commun. 2021; 12(1):4869. PMC: 8357947. DOI: 10.1038/s41467-021-25030-7. View

18.

Carissimo G, Xu W, Kwok I, Abdad M, Chan Y, Fong S . Whole blood immunophenotyping uncovers immature neutrophil-to-VD2 T-cell ratio as an early marker for severe COVID-19. Nat Commun. 2020; 11(1):5243. PMC: 7568554. DOI: 10.1038/s41467-020-19080-6. View

19.

Kassambara A, Herviou L, Ovejero S, Jourdan M, Thibaut C, Vikova V . RNA-sequencing data-driven dissection of human plasma cell differentiation reveals new potential transcription regulators. Leukemia. 2021; 35(5):1451-1462. PMC: 8102200. DOI: 10.1038/s41375-021-01234-0. View

20.

Morgan D, Tergaonkar V . Unraveling B cell trajectories at single cell resolution. Trends Immunol. 2022; 43(3):210-229. DOI: 10.1016/j.it.2022.01.003. View